-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On January 4, Genting Shinya announced that the Food and Drug Administration of Taiwan, China has accepted the New Drug Marketing Application (NDA) of Sacituzumab Govitecan for the treatment of unresectable locally advanced or metastatic adult patients.
The English trade name of Gosartuzumab is Trodelvy®.
In November 2021, Genting Xinyao announced the key results of the phase 2b EVER-132-001 study of gosartuzumab, which reached its primary endpoint with an objective response rate (ORR) of 38.
Note: The original text has been deleted